Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.50 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638512 | 0.88 | MAOB (0.50) | MAOBDCPSNR4A2NR4A1NR4A3 | |
| SCHEMBL24968830 | 0.85 | MAOB (0.53) | MAOBDCPSSLC6A2SLC6A4MAOA | |
| SCHEMBL6979333 | 0.82 | HTR6 (0.46) | MAOBDCPSNR4A2NR4A1NR4A3 | |
| SCHEMBL14380641 | 0.82 | DCPS (0.43) | MAOBDCPSNR4A2NR4A1NR4A3 | |
| SCHEMBL26377963 | 0.81 | NR4A2 (0.60) | MAOBDCPSNR4A2SLC6A2SLC6A4 | |
| SCHEMBL5921916 | 0.80 | RAB9A (0.56) | MAOBNR4A2INPPL1MAOARAB9A | |
| SCHEMBL13712203 | 0.80 | MAOB (0.47) | MAOBDCPSNR4A2NR4A1NR4A3 | |
| SCHEMBL4638661 | 0.79 | MAOB (0.50) | MAOBDCPSNR4A2RAB9ANPC1 | |
| SCHEMBL13709217 | 0.79 | NR4A2 (0.43) | MAOBDCPSNR4A2NR4A1NR4A3 | |
| SCHEMBL6957885 | 0.79 | MAOB (0.46) | MAOBDCPSNR4A2NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777032-B2 | N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7585975-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ARRAY BIOPHARM, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ABL1, ERBB2, FLT3 | MAOB 2048/4885DCPS 3748/4885NR4A2 1516/4885 |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | MAOB 2048/4885DCPS 3748/4885NR4A2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.